|4.||Rubella (German Measles)
|1.||Monath, Thomas P: 19 articles (08/2011 - 01/2002)|
|2.||Galler, Ricardo: 18 articles (04/2015 - 01/2002)|
|3.||Guirakhoo, Farshad: 14 articles (07/2010 - 01/2002)|
|4.||Monath, T P: 12 articles (12/2006 - 02/2000)|
|5.||Bonaldo, Myrna C: 9 articles (03/2014 - 01/2002)|
|6.||Freire, Marcos S: 8 articles (08/2015 - 01/2002)|
|7.||Hansen, Immo A: 8 articles (01/2015 - 05/2005)|
|8.||Guirakhoo, F: 8 articles (09/2004 - 02/2000)|
|9.||Lan, Que: 7 articles (07/2015 - 10/2003)|
|10.||Dickens, Joseph C: 7 articles (05/2014 - 01/2009)|
03/15/2012 - "Effective vaccines against yellow fever have been available for almost 70 years and are responsible for a significant reduction of occurrences of the disease worldwide; however, approximately 200,000 cases of yellow fever still occur annually, principally in Africa. "
10/01/2007 - "A greater understanding of this condition is essential to assuring safe and effective prevention of yellow fever and vaccination against other arboviral diseases for which 17D-based vaccines are being developed."
09/01/2015 - "This randomised, double-blind, multicentre study with children nine-23 months old evaluated the immunogenicity of yellow fever (YF) vaccines prepared with substrains 17DD and 17D-213/77. "
08/11/2011 - "The results will be useful in defining the level of seroprotection in clinical studies of new yellow fever vaccines."
03/01/2008 - "This study evaluated the safety of two yellow fever (YF) vaccines [Stamaril and Vacina Contra Febre Amarela (VCFA)]. "
05/01/2001 - "The resulting chimeric virus contains the antigens responsible for protection against West Nile but retains the replication efficiency of yellow fever 17D. "
01/01/2014 - "Interestingly, we found that the peak of the yellow fever-specific CD8 T cell response was determined by the rate of T cell proliferation and not by the precursor frequency of antigen-specific cells as has been suggested in several studies in mice. "
11/29/2010 - "CD8+ gamma-delta TCR+ and CD4+ T cells produce IFN-γ at 5-7 days after yellow fever vaccination in Indian rhesus macaques, before the induction of classical antigen-specific T cell responses."
07/01/2004 - "We investigated whether the cost of an immune response in the yellow fever mosquito, Aedes aegypti, is modulated by the antigen that activates the melanization immune response. "
11/01/2003 - "Cells within those tissues stained positively with a polyclonal antibody against YFV antigens (1:1,600 dilution), and yellow fever was diagnosed for the first time in the brown howler in the area."
09/01/2005 - "In this study, we compare the neurovirulence of ChimeriVax vaccine candidates in suckling mice inoculated by the intracerebral (IC) route with graded doses of the test article or yellow fever 17D vaccine as a reference control. "
05/01/2010 - "Cost, efficacy, and safety concerns led to the development of a single-dose live attenuated virus vaccine (SA14-14-2) and more recently, to the licensure in the United States, Europe, and Australia of a purified inactivated, tissue culture-based JE vaccine (IC51; Intercell AG, Vienna, Austria) and the soon-to-be-licensed live-attenuated yellow fever-JE chimeric vaccine (ChimeriVax-JE; Sanofi Pasteur, Lyon, France). "
11/01/2006 - "Four chimeric yellow fever (YF) 17D-dengue (DEN) candidate vaccine viruses (ChimeriVax-DEN; Acambis, Cambridge, MA) were characterized in Aedes aegypti and Ae. albopictus mosquitoes collected from Thailand. "
01/15/2002 - "ChimeriVax is a live, attenuated recombinant virus constructed from yellow fever (YF) 17D in which the envelope protein genes of YF 17D are replaced with the corresponding genes of another flavivirus. "
02/01/2000 - "ChimeriVax-JE meets preclinical safety and efficacy requirements for a human vaccine; it appears safer than yellow fever 17D vaccine but has a similar profile of immunogenicity and protective efficacy."
02/20/2006 - "A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins."
04/30/1986 - "Topographical analysis of epitope relationships on the envelope glycoprotein of yellow fever 17D vaccine and the wild type Asibi parent virus."
01/01/2014 - "Flaviviruses, such as dengue, West Nile, and yellow fever viruses, assemble as fusion-incompetent particles and subsequently undergo a large reorganization of their glycoprotein envelope resulting in formation of mature infectious virions. "
02/01/2011 - "Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs."
01/20/2010 - "The conserved M2e peptide of influenza A virus was randomly inserted into the yellow fever-specific NS1 glycoprotein of ChimeriVax-JE. "
|5.||Malathion (Karbofos)FDA LinkGeneric
01/01/1970 - "In view of the threat of additional yellow fever epidemics in East Africa and recent successes in the use of malathion applied by the ultra-low-volume technique against insect vectors, field trials were initiated in November 1968 to test the efficacy of this method against Aedes simpsoni. "
08/01/2013 - "This study evaluated how larval rearing temperature influences the impact of malathion on the fitness of the yellow fever mosquito Aedes aegypti. "
|6.||Yellow Fever Vaccine (Vaccine, Yellow Fever)FDA Link
04/01/2007 - "Over past decades the 17DD yellow fever vaccine has proved to be effective in controlling yellow fever and promises to be a vaccine vector for other diseases, but the cellular and molecular mechanisms by which it elicits such broad-based immunity are still unclear. "
09/01/2015 - "The Department of Health regulates the designation of yellow fever vaccination centres (YFVCs) in the Republic of Ireland to ensure appropriate standards in the safe, effective use of yellow fever vaccine for overseas travellers. "
01/01/2015 - "Even with serious and rare adverse events, yellow fever vaccine is the best way to avoid yellow fever, a disease of high lethality and should be used routinely in endemic areas, and on people from non-endemic areas that could be exposed, according to a careful risk-benefit analysis. "
03/01/2014 - "Yellow fever vaccine recommendations were revised to include areas in Brazil previously not considered at risk for yellow fever. "
12/02/2013 - "Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) is a rare and serious adverse event of the yellow fever (YF) vaccine that mimics wild-type YF. "
|7.||Immunoglobulin M (IgM)IBA
06/01/2003 - "Examinations were conducted on lyophilized sera from 3 fatal yellow fever cases and 4 fresh sera from 3 fatal cases and one from a symptomatic patient (positive IgM against yellow fever virus). "
05/08/1999 - " Of the 281 people covered in the serosurvey, 16 (6%) were positive for IgM antibody to yellow fever. "
05/08/1999 - "Of the 281 people covered in the serosurvey 16 (6%) were positive for IgM antibody to yellow fever. "
01/01/1999 - "61 (14%) persons had IgM to WSLV only, while 9 (2%) persons had heterologous IgM to WSLV and two other flaviviruses, namely yellow fever and Uganda S viruses. "
09/01/1992 - "An evaluation of the IgM antibody immune response against yellow fever using strain 17D was carried out by MAC-ELISA and PRNT. "
|8.||Proteins (Proteins, Gene)IBA
10/19/2012 - "ChimeriVax-WN02 is a live, attenuated chimeric vaccine for protection against West Nile virus (WNV) produced by insertion of the genes encoding the pre-membrane (prM) and envelope (E) proteins of WNV (strain NY99) into the yellow fever 7D vaccine virus. "
12/01/2013 - "Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins."
01/01/2013 - "Using the 2-D Difference Gel Electrophoresis (2-D DIGE) procedure, we investigated the abundance of up to 898 proteins from the Yellow Fever and dengue virus vector, Aedes aegypti, during ageing. "
10/01/2012 - "These proteins can have profound effects on female behavior in the yellow fever mosquito Aedes aegypti and the Asian tiger mosquito Aedes albopictus. "
01/01/2008 - "Manual annotation of the Gr family in the genome sequence of the yellow-fever mosquito, Aedes aegypti, yielded a total of 114 potential proteins encoded by 79 genes. "
05/01/1992 - "Eight monoclonal antibodies (MAbs) derived using yellow fever (YF) virus (French viscerotropic virus strain) labelled the nuclei (wild-type strains) and/or the nucleoli (vaccine strains) of cells infected with different strains of YF virus. "
07/01/1989 - "Monoclonal antibodies (MAbs) against the Asibi wild-type strain of yellow fever (YF) virus were prepared and characterized. "
07/01/1988 - "Monoclonal antibodies (MABs) YEL-2 induced by the vaccine FNS Dakar yellow fever (YF) virus were characterized for their capacity to enter into serological reactions and to react with heterologous flaviviruses. "
11/01/1986 - "Here we report for the first time the enhancement of virus virulence in mice using monoclonal antibodies (MAbs) prepared against yellow fever (YF) viruses. "
07/01/1985 - "Monoclonal antibodies prepared against vaccine strains of yellow fever (YF) virus were initially characterized by fluorescence microscopy of Vero cells infected with YF virus strain 17D. "
11/01/2015 - "Yellow fever 17D vaccine is one of the oldest live-attenuated vaccines in current use that is recognized historically for its immunogenic and safe properties. "
10/05/2015 - "The worldwide use of yellow fever (YF) live attenuated vaccines came recently under close scrutiny as rare but serious adverse events have been reported. "
01/01/2014 - "The yellow fever 17D virus as a platform for new live attenuated vaccines."
01/01/2007 - "The attenuated yellow fever 17D virus strain has been used for human vaccination for 70 years and has several characteristics that are desirable for the development of new, live attenuated vaccines. "
11/07/2005 - "The yellow fever (YF) 17D vaccine is one of the most successful live attenuated vaccines available. "
10/01/2008 - "There is no data to support that immunization of the dono prior to the graft could confer protection against yellow fever to the recipient. "
09/01/2013 - "Immunization using live attenuated vaccines represents a contra-indication after solid organ transplantation (SOT): consequently, transplant candidates planning to travel in countries where yellow fever is endemic should be vaccinated prior to transplantation. "
04/01/2009 - "Live attenuated vaccines (such as yellow fever, measles-mumps-rubella, or chicken pox) are contra-indicated in solid organ transplant recipients and, when indicated, should be administered prior to transplantation, particularly in foreign-born patients highly likely to visit friends and relatives in endemic areas. "
04/01/2015 - "We review the available studies on LAVV, such as varicella zoster, measles-mumps-rubella, influenza, yellow fever, polio, and Japanese encephalitis vaccines in transplant patients. "
04/01/2001 - "Acute disseminated encephalomyelitis (ADEM), a monophasic and multifocal illness of the white and grey matter, has been observed following various viral or bacterial infections as well as vaccine injections for diseases such as pertussis, tetanus and yellow fever. "
08/01/1986 - "We compared the immune responses of Senegalese children to the separate or simultaneous injections of yellow fever and hepatitis B vaccines. "
10/31/1920 - "Injections into guinea pigs of the blood and the emulsions of liver and kidney obtained at autopsy from a fatal case of yellow fever in Merida induced in some of these animals, after a period of several days incubation, a rise of temperature which lasted 1, 2, or more days. "
03/01/2003 - "In a randomized study, 48 healthy volunteers either were immunized against yellow fever, polio, diphtheria, and tetanus (the group receiving intervention with nonchlamydial antigen) or received saline injections (the placebo group). "
04/01/2015 - "The recent changes concern the schedule of injections: primovaccination DTCaPolio of children and boosters for adults, accelerated schedule of Japanese encephalitis and hepatitis B immunization, preexposure rabies immunization and vaccination against yellow fever; and the indications of poliomyelitis vaccine, immunization of children against Japanese encephalitis and conjugated vaccines against meningococcal meningitis."
|3.||Hormone Replacement Therapy (Therapy, Hormone Replacement)
07/04/2008 - "The genesis of these differences is uncertain but not entirely related to gonadal hormones (differences are seen in pre-pubertal and post-menopausal subjects not on hormone replacement therapy) or female sex (males had greater serological response for pneumococcal, diphtheria, yellow fever, Venezuelan equine encephalitis and in some studies with rabies vaccine. "
03/01/2013 - "In this study, we performed a combination of matrix assisted laser desorption ionization time of flight (MALDI-TOF) and electrospray ionization quadrupole time of flight (ESI-Q-TOF) mass spectrometry to analyze the peptidome of the brain and the neurohemal organs of the Australian sheep blowfly Lucilia cuprina and compared the data with those of related flies such as the gray flesh fly Sarcophaga (=Neobellieria) bullata; the cabbage root fly Delia radicum, the fruit fly Drosophila melanogaster, and the yellow fever mosquito, Aedes aegypti. "
09/01/2012 - "Age, last minute travel (17%) and neurological and psychiatric diseases were the most frequent factors that influenced Yellow fever vaccination and malaria chemoprophylaxis, with more than one tenth of the travellers reporting at least one risk factor for which adjusted advice may be necessary. "
07/19/2001 - "Accordingly, vaccinations for yellow fever and hepatitis were the most commonly indicated and implemented vaccinations, and more than 50% received antimalarial chemoprophylaxis."
01/01/2012 - "Except for yellow fever and encephalitis B, effective vaccines remain unavailable against most infectious diseases, and prevention is based mainly upon vector control and chemoprophylaxis. "
10/01/2009 - "In addition to fight against vectors (insecticides) and disease prevention (vaccination against yellow fever, chemoprophylaxis against malaria), insect repellents applied on the skin could help reduce the heavy burden related to these diseases. "